跳至主要内容
临床试验/EUCTR2016-002279-88-NL
EUCTR2016-002279-88-NL进行中(未招募)1 期

The physiology of glucagon-like peptide-l receptor expression in patients with endogenous hyperinsulinism: correlation with histopathology - Exendin-CHI

European Commission0 个研究点目标入组 40 人开始时间: 2017年11月27日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Biochemically and clinically proven endogenous congenital hyperinsulinism:
  • - Unresponsive to medical treatment (diazoxide)
  • - Indication for 18F-DOPA PET/CT based on mutation analysis
  • - Standard imaging (18F-DOPA PETICT) not older than 8 weeks
  • - < 16 years old
  • - informed consent signed by parents or legal guardians of the patient.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 40
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Genetically proven diffuse CHI (presenting with a homozygous or compound heterozygous ABCCS/KCNJ11 mutation)
  • - Calculated creatinine clearance below 40 ml/min
  • - Evidence of other malignancy than insulin producing tumors in conventional imaging (suspicious liver, bone and lung lesions based on CT)
  • - Age > 16 years
  • - No signed informed consent

研究者

相似试验